EHA 2022 | Itacitinib plus alemtuzumab for patients with T-PLL
Tapan Kadia, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights data coming from a Phase IB study of itacitinib combined with alemtuzumab in patients with T-cell prolymphocytic leukemia (T-PLL). To date, alemtuzumab has been the most effective therapy available for patients with T-PLL, although responses are not durable. In this study, patients initially treated with single agent itacitinib reported improvements in symptoms including rash and appetite. Following the addition of alemtuzumab, a high overall response rate (ORR) of 88% was observed in newly diagnosed patients, and an ORR of 57% in previously treated patients. A future study of the combination therapy, without the initial 2-week single agent itacitinib, is planned. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Consulting: AbbVie, Agios, Daiichi Sankyo, Genentech, Jazz, Liberum, Novartis, Pfizer, Pinot Bio, Sanofi-Aventis, Servier
Grant/Research Support: AbbVie, Amgen, Ascentage, Astellas, Astex, AstraZeneca, BMS, Celgene, Cellenkos, Cyclacel, Delta-Fly, Genentech, Genfleet, Glycomimetics, Iterion, Jazz, Pfizer, Pulmotech, Regeneron
Speaker’s Bureau: Cure, Hikma
Honoraria: Genzyme
